Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
Viviant/Combriza (Osteoporosis) - Forecast and Market Analysis to 2022

Global viviant/combriza market: Latest market analysis presented


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-03-14 02:51:04 - Viviant/Combriza (Osteoporosis) - Forecast and Market Analysis to 2022 - a new market research report on companiesandmarkets.com

Viviant/Combriza (Osteoporosis) - Forecast and Market Analysis to 2022 - We have released our new PharmaPoint Drug Evaluation report, "Viviant/Combriza (Osteoporosis) - Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the gold-standard bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lillys blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs

 

 

with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.

Viviant/Conbriza (bazedoxifene) is a SERM produced by Pfizer for the treatment of postmenopausal osteoporosis. It has been approved in Europe and Japan, but is not available in the United States. The FDA rejected the drug due to serious side effects that included stoke and blood clots. Despite its EMA approval, it is marketed only in Italy and Spain. Viviant works by down-regulating the estrogen receptor alpha (ERa) by suppressing cyclin D1 promoter activity and by preventing osteoclast differentiation downstream (Lewis-Wambi et al., 2011). This causes a slowing of bone resorption by osteoclasts.

Note: This is upcoming report and will be delivered within 24 hrs of the purchase (excluding weekends).

Scope

- Overview of Osteoporosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Viviant/Combriza including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Viviant/Combriza for the top three countries from 2012 to 2022.
- Sales information covered for Italy, Spain and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Viviant/Combriza performance
- Obtain sales forecast for Viviant/Combriza from 2012-2022 in top three countries (Italy, Spain and Japan)

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com